Year: 2014
Type: article
Abstract: Gene discovery efforts and functional studies have credentialed the JAK-STAT signaling pathway as an important pathway contributing to malignant transformation. 1 On the basis of these observations, JAK2 kinase inhibitors have been developed for clinical use, and ruxolitinib, a JAK2/JAK1 inhibitor is approved for primary myelofibrosis. 2 , 3 More importantly, JAK2 inhibitors with different pharmacokinetic properties and off-target effects have entered clinical trials for use in chronic myeloid leukemia (CML), acute lymphoblastic T-cell leukemia and myelodysplastic syndrome patients ( http://clinicaltrials.gov/ct2/results?term=ruxolitinib&Search=Search ). Recent studies have suggested a role for JAK2 kinase inhibition for patients with breast cancer, lung cancer and pancreatic tumors 4 and clinical trials are evaluating the role of JAK2 inhibitors in epithelial tumors.
Source: Leukemia
DOI: 10.1038/leu.2014.152
Authors: E Grundschober, A Hoelbl-Kovacic, N Bhagwat, B Kovacic, R Scheicher, E Eckelhart, K Kollmann, M Keller, F Grebien, K-U Wagner, R L Levine, V Sexl
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,096
OpenAlex ID: W2092408419